

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ILLUMINA, INC.,
Petitioner,

v.

THE TRUSTEES OF COLUMBIA UNIVERSITY
IN THE CITY OF NEW YORK,
Patent Owner.

Case IPR2018-00291
Patent 9,718,852 B2

Before JENNIFER MEYER CHAGNON, JAMES A. WORTH, and
MICHELLE N. ANKENBRAND, *Administrative Patent Judges*.

WORTH, *Administrative Patent Judge*.

DECISION

Institution of *Inter Partes* Review
35 U.S.C. § 314(a)

I. INTRODUCTION

On December 8, 2017, Illumina, Inc. (“Illumina” or “Petitioner”) filed a Petition (Paper 1, “Pet.”) requesting an *inter partes* review of claim 1 (the “challenged claim”) of U.S. Patent No. 9,718,852 B2 (“the ‘patent’”). On March 27, 2018, The Trustees of Columbia

Columbia Ex. 2019
Illumina, Inc. v. The Trustees
of Columbia University
in the City of New York

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

ILLUMINA, INC.,
Petitioner,

v.

THE TRUSTEES OF COLUMBIA UNIVERSITY
IN THE CITY OF NEW YORK,
Patent Owner.

Case IPR2018-00291
Patent 9,718,852 B2

Before JENNIFER MEYER CHAGNON, JAMES A. WORTH, and
MICHELLE N. ANKENBRAND, *Administrative Patent Judges*.

WORTH, *Administrative Patent Judge*.

DECISION
Institution of *Inter Partes* Review
35 U.S.C. § 314(a)

I. INTRODUCTION

On December 8, 2017, Illumina, Inc. (“Illumina” or “Petitioner”) filed a Petition (Paper 1, “Pet.”) requesting an *inter partes* review of claim 1 (the “challenged claim”) of U.S. Patent No. 9,718,852 B2 (Ex. 1001, “the ’852 patent”). On March 27, 2018, The Trustees of Columbia University in the

City of New York (“Columbia” or “Patent Owner”) filed a Preliminary Response (Paper 8, “Prelim. Resp.”).

Institution of an *inter partes* review is authorized by statute when “the information presented in the petition filed under [35 U.S.C. §] 311 and any response filed under [35 U.S.C. §] 313 shows that there is a reasonable likelihood that the petitioner would prevail with respect to at least 1 of the claims challenged in the petition.” 35 U.S.C. § 314(a). For the reasons set forth below, we determine that Petitioner has demonstrated that there is a reasonable likelihood that claim 1 is unpatentable, and we institute an *inter partes* review of claim 1 based on the grounds set forth in the Petition.

A. *Related Matters*

The parties note as related IPR2012-00007 (Final Written Decision, Paper 140, Ex. 1005) with respect to U.S. Patent No. 7,790,869; IPR2012-00006 (Final Written Decision, Paper 128, Ex. 1006) with respect to U.S. Patent No. 7,713,698; and IPR2013-00011 (Final Written Decision, Paper 130, Ex. 1007) with respect to U.S. Patent No. 8,088,575. Pet. 1; Paper 4, 1. In these proceedings, the Board held all challenged claims unpatentable. *Id.* The Board decisions were affirmed *sub. nom. Trustees of Columbia Univ. v. Illumina, Inc.*, 620 Fed. Appx. 916, 927–28, 934 (Fed. Cir. 2015) (*see* Ex. 1008).

The parties state that Petitioner has filed petitions for *inter partes* review of U.S. Patents Nos. 9,719,139, 9,708,358, 9,725,480, 9,868,985 (“the ’852, ’139, ’358, and ’480 patents”) alleged to be owned by Columbia, PTAB Case Nos. IPR2018-00291, -318, -322, -385, -797. Paper 4, 2; Paper 5, 1; Paper 9, 1. Patent Owner states that the ’852, ’139, ’358, and ’480 patents were asserted against Illumina in *Trustees of Columbia University v.*

Illumina, Inc., C.A. No. 17-cv-973-GMS (D. Del.). *Id.* Patent Owner further states that Columbia previously asserted related U.S. Patents Nos. 7,790,869, 7,713,698, and 8,088,575 (“the ’869, ’698, and ’575 patents”) against *Illumina* in *Trustees of Columbia University v. Illumina, Inc.*, C.A. No. 12-cv-376 (D. Del.). *Id.*

Patent Owner also points to other proceedings in which *Illumina* is involved that relate to patents owned by *Illumina*. *See* Paper 4, 2; Paper 13, 1.

B. *The ’852 Patent (Ex. 1001)*

The ’852 patent is titled “Massive Parallel Method for Decoding DNA and RNA” and relates to a “system for DNA sequencing by the synthesis approach which employs a stable DNA template, which is able to self prime for the polymerase reaction, covalently linked to a solid surface such as a chip, and 4 unique nucleotides analogues.” Ex. 1001, 4:25–31.

The ’852 patent discloses that electrophoresis was a bottleneck for high-throughput DNA sequencing and mutation detection projects. *Id.* at 2:16–18. It was known to perform sequencing without electrophoresis, using a chip format and laser-induced fluorescent detection for DNA sequencing. *Id.* at 2:19–27. The ’852 patent discloses that long stretches of the same bases cannot be identified unambiguously with a pyrosequencing method. *Id.* at 2:44–46. The ’852 patent also describes limited success in the prior art for the incorporation of 3'-modified-nucleotides by DNA polymerase. *Id.* at 2:52–53.


The approach disclosed in the ’852 patent is to make nucleotide analogues by linking a unique label, such as a fluorescent dye or a mass tag, through a cleavable linker to the nucleotide base or an analogue of the

nucleotide base, such as to the 5-position of the pyrimidines (T and C) and to the 7-position of the purines (G and A), to use a small cleavable chemical moiety to cap the 3'-OH group of the deoxyribose to make it nonreactive, and to incorporate the nucleotide analogues into the growing DNA strand as terminators. *Id.* at 3:4–13; *see also id.* at 5:40–41. The approach disclosed in the '852 patent is further to incorporate nucleotide analogues, which are labeled with cleavable, unique labels, such as fluorescent dyes, to mass tags and where the 3'-OH is capped with a cleavable chemical moiety, such as either a MOM group (-CH₂OCH₃) or an allyl group (-CH₂CH=CH₂), into the growing strand DNA as terminators. *Id.* at 3:44–51; *see also id.* at 5:43–44.

C. Illustrative Claim

Claim 1, reproduced below, is the sole challenged claim and is illustrative of the subject matter:

1. An adenine deoxyribonucleotide analogue having the structure:



wherein R (a) represents a small, chemically cleavable, chemical group capping the oxygen at the 3' position of the deoxyribose of the deoxyribonucleotide analogue, (b) does not interfere with recognition of the analogue as a substrate by a DNA polymerase, (c) is stable during a DNA polymerase reaction, and (d) does not contain a ketone group;

wherein OR is not a methoxy group or an ester group;

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.